Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 40Unknown 7Terminated 6Withdrawn 3Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma 3Sarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Recurrence 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Hodgkin Disease 1Disease Progression 1

Interventions

Rituximab 20Cyclophosphamide 18Etoposide 11Vincristine 10Doxorubicin 10fludarabine phosphate 9Prednisone 9Filgrastim 9Radiotherapy 8Peripheral Blood Stem Cell Transplantation 8Cytarabine 8Methotrexate 7Melphalan 7Dexamethasone 6fludarabine 4Cyclosporine 4Antilymphocyte Serum 4duvelisib 3belinostat 3Thiotepa 3Tacrolimus 3Nivolumab 3Mycophenolic Acid 3Lenalidomide 3Ifosfamide 3Gemcitabine 3Carmustine 3Busulfan 3Alemtuzumab 3sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma × Ifosfamide × Clear all
NCT02408042 2017-06-27

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Western Regional Medical Center

Phase 1/2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT00829205 2013-08-26

Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT00801918 2013-05-15

Denileukine Diftitox for Relapsed ALCL

Columbia University

Phase 2 Withdrawn
Lymphoid

Lymphoma, Recurrence, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡